P. Diana et al. / European Journal of Medicinal Chemistry 37 (2002) 267–272
271
132.6 (s), 137.0 (s), 160.9 (s). Anal. Calc. for
Acknowledgements
C17H15N5O2 (321.33): C 63.54, H 4.70, N 21.80. Found:
C 63.52, H 4.53, N 21.63%.
This work was financially supported by Ministero
dell’Istruzione dell’Universita` e della Ricerca. A preli-
minary account of this work was presented at the First
Italian-Swiss Meeting on Medicinal Chemistry, Torino,
September 1997. We thank the National Cancer Insti-
tute (Bethesda, MD) and especially Dr V.L. Narayanan
and his team for the antitumour tests reported in this
paper.
The reaction mixture obtained from the reaction of
1a with ethylcyanoacetate (2d) was eluted with
dichloromethane:ethyl acetate (9:1), the compound
eluted was (4f) yield 60%, m.p. 202–205 °C; IR cm−1
3260 (very broad NH2), 2233 (CN), 1689 (CO); 1H-
NMR l 1.39 (3H, t, J=7.1 Hz, CH3), 2.28 (3H, s,
CH3), 4.38 (2H, q, J=7.1 Hz, CH2), 7.31–7.43 (5H, m,
Ph), 12.05 (1H, s, NH), 13.29 (1H, s, NH); 13C-NMR l
10.8 (q), 13.8 (q), 62.2 (t), 81.3 (s), 105.7 (s), 115.0 (s),
117.7 (s), 124.8 (s), 126.2 (d), 126.9 (d), 128.8 (d), 130.9
(s), 132.5 (s), 137.0 (s), 160.6 (s). Anal. Calc. for
C17H15N5O2 (321.33): C 63.54, H 4.70, N 21.80. Found:
C 63.47, H 4.78, N 21.68. Further elution with
dichloromethane:methanol (9:1) gave compound (3f)
yield 35%, m.p. 128–130 °C; IR cm−1 3249 and 3200
References
[1] G. Cirrincione, A.M. Almerico, E. Aiello, G. Dattolo, Adv.
Heterocyclic Chem. 48 (1990) 65–175.
[2] G. Dattolo, G. Cirrincione, A.M. Almerico, E. Aiello, S. Gri-
maudo, P. Diana, L. Rausa, L. Dusonchet, L. Crosta, M.
Tolomeo, V. Candiloro, M. Meli, Il Farmaco 48 (1993) 191–194.
[3] G. Cirrincione, A.M. Almerico, G. Dattolo, E. Aiello, P. Diana,
S. Grimaudo, P. Barraja, F. Mingoia, R.A. Gancitano, Eur. J.
Med. Chem. 29 (1994) 889–891.
[4] G. Cirrincione, A.M. Almerico, P. Diana, S. Grimaudo, P.
Barraja, F. Mingoia, G. Dattolo, E. Aiello, Il Farmaco 51 (1996)
275–277.
1
(NH2), 2232 (CN), 2216 (CN), 1685 (CO); H-NMR l
1.28 (3H, t, J=7.3 Hz, CH3 Z), 1.33 (3H, t, J=7.3 Hz,
CH3 E), 2.25 (3H, s, CH3), 4.29 (2H, q, J=7.3 Hz,
CH2 Z), 4.34 (2H, q, J=7.3 Hz, CH2 E), 7.30–7.48
(5H, m, Ph), 11.78 (1H, s, NH A), 12.16 (1H, s, NH E
and Z), 13.32 (1H, s, NH Z); 13C-NMR l 10.8 (q), 13.8
(q), 62.2 (t), 81.3 (s), 105.7 (s), 115.0 (s), 117.7 (s), 124.8
(s), 126.2 (d), 126.9 (d), 128.7 (s), 128.8 (d), 130.9 (s),
137.0 (s), 160.6 (s). Anal. Calc. for C17H15N5O2
(321.33): C 63.54, H 4.70, N 21.80. Found: C 63.52, H
4.73, N 21.73%.
[5] (a) U.S. Lucas, A.T. Huang, in: H.F. Siegler (Ed.), Development
in Oncology, vol. 5, Martinusnijhoff, The Hague, The Nether-
lands, 1982, p. 382;
(b) S. Viviani, G. Bonadonna, A. Santoro, V. Bonfante, M.
Zanin, L. Devizzi, F. Soncini, P. Valagussa, J. Clin. Oncol. 14
(1996) 1421–1430.
[6] P. Diana, P. Barraja, A. Lauria, A.M. Almerico, G. Cirrincione,
A.G. Loi, E. Congeddu, C. Musiu, M. Putzolu, P. La Colla,
Eur. J. Med. Chem. 34 (1999) 353–360.
[7] P. Diana, P. Barraja, A. Lauria, A.M. Almerico, G. Dattolo, G.
Cirrincione, Synthesis (1999) 2082–2086.
[8] (a) E.S. Newlands, M.F.G. Stevens, S.R. Wedge, R.T. Wheel-
house, C. Brock, Cancer Treat. Rep. 23 (1997) 35–61;
(b) N.M. Bleehen, E.S. Newlands, S.M. Lee, N. Thatcher, P.
Selby, A.H. Calvert, G.J.S. Rustin, M. Brampton, M.F.G.
Stevens, J. Clin. Oncol. 13 (1995) 910–914;
The reaction mixture obtained from the reaction of
1b with malononitrile (2b) was eluted with
dichloromethane:ethyl acetate (8:2), the compound
eluted was (4g) yield 80%, m.p. 270 °C; IR cm−1 3418
1
and 3318 (NH2), 2230 (CN), 2215 (CN); H-NMR l
2.81 (3H, s, CH3), 7.47–7.62 (5H, m, Ph), 8.56 (2H, s,
NH2); 13C-NMR l 12.8 (q), 84.1 (s), 105.8 (s), 114.4 (s),
116.1 (s), 119.9 (s), 128.7 (d), 128.9 (d), 129.5 (d), 130.5
(s), 131.8 (s), 144.3 (s), 144.7 (s). Anal. Calc. for
C15H10N6 (274.28): C 65.68, H 3.68, N 30.64. Found: C
65.52, H 3.55, N 30.52%.
(c) S.M. O’Reilly, E.S. Newlands, M.G. Glaser, M. Brampton,
J.M. Rice-Edwards, R.D. Illinworth, P.G. Richards, C. Ken-
nard, I.R. Colquhoun, P. Lewis, M.F.G. Stevens, Eur. J. Cancer
29A (1993) 940–943;
(d) E.S. Newlands, G.R.P. Blackledge, J.A. Slack, G.J.S. Rustin,
D.B. Smith, N.S.A. Stuart, C.P. Quarterman, R. Hoffman,
M.F.G. Stevens, M.H. Brampton, A.C. Gibson, Br. J. Cancer 65
(1992) 287–291.
3.1.3. Cyclisation of ethyl
2-cyano-2-(pyrrol-2-yl-hydrazono)acetates 3e and f
A mixture of 3e and f (2 mmol) and concentrated
sulfuric acid (20 mL) was kept at r.t. for 1 h. The
mixture was then poured into cold water and neu-
tralised by addition of ammonia, and the resulting
products were collected by filtration to give the pyrrolo-
triazine 4e (84%) and 4f (90%).
[9] P. Diana, P. Barraja, A. Lauria, A.M. Almerico, G. Dattolo, G.
Cirrincione, Il Farmaco 55 (2000) 200–201.
[10] (a) J.G. Erickson, Chem. Heterocycl. Compd. 10 (1956) 44–137;
(b) R.L. Jones, J.R. Kershaw, Rev. Pure Appl. Chem. 21 (1971)
23–48;
(c) H. Neunhoeffer, P.F. Wiley, Chem. Heterocycl. Compd. 33
(1978) 189–574;
(d) H. Neunhoeffer, in: A.R. Katrizky, C.W. Rees (Eds.), Com-
prehensive Heterocyclic Chemistry, vol. 3, Pergamon Press, Ox-
ford, 1984, pp. 385–456;
3.2. Pharmacology
(e) E.S.H. El Ashry, N. Rashed, M. Taha, E. Ramadan, Adv.
Heterocycl. Chem. 59 (1994) 39–177.
3.2.1. Inhibition of tumour cell growth assay
The procedure for the GI50 determination was per-
formed according to the NCI protocol [16].
[11] Y. Kurasawa, M. Kanoh, Y. Kamigaki,
M Okiyama, A.
Takada, Y. Okamoto, J. Heterocyclic Chem. 25 (1988) 1015–
1018.